相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA)
Tatsuya Ioka et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2023)
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Marina C. Garassino et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
Jean marc Phelip et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population
Yasuhisa Ando et al.
ONCOLOGY LETTERS (2022)
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer
Yuichiro Doki et al.
CANCER MEDICINE (2022)
The epidemiological trends of biliary tract cancers in the United States of America
Yong Jiang et al.
BMC GASTROENTEROLOGY (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Juan W Valle et al.
LANCET ONCOLOGY (2021)
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliarytract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
Changhoon Yoo et al.
LANCET ONCOLOGY (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
Oliver Clements et al.
JOURNAL OF HEPATOLOGY (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
Sylvie Job et al.
HEPATOLOGY (2020)
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
Sarina A. Piha-Paul et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience
Longrong Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
C. Morizane et al.
ANNALS OF ONCOLOGY (2019)
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Benjamin A. Weinberg et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital
Ria Winkelmann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
Andreas R. de Biasi et al.
CLINICAL CANCER RESEARCH (2014)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)